[Federal Register Volume 61, Number 222 (Friday, November 15, 1996)]
[Notices]
[Pages 58575-58576]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-29255]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Prospective Grant of a Partially Exclusive License: Pseudomonas-
Exotoxin-Based Fusion Protein Cancer Therapy
AGENCY: National Institutes of Health, Public Health Service, DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice in accordance with 35 U.S.C. 209(c)(1) and 37
CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH),
Department of Health and Human Services, is contemplating the grant of
a partially exclusive license in the United States and abroad to
practice the inventions embodied in U.S. Patent Application Serial No.
08/077,252, entitled ``Recombinant
[[Page 58576]]
Disulfide-Stabilized Polypeptide Fragments Having Binding
Specificity''; U.S. Patent Application Serial Nos. 08/405,615, 08/
463,480, and 08/461,234, all entitled ``Recombinant Pseudomonas
Exotoxin with Increased Activity,'' and U.S. Patent Application No. 08/
331,398, entitled ``Single-Chain B3 Antibody Fusion Proteins and Their
Uses'' to The Therapeutics Division of Boehringer-Mannheim Corporation
having a place of business in Rockville, MD. The patent rights in these
inventions have been assigned to the United States of America.
SUPPLEMENTARY INFORMATION: The prospective exclusive license will be
royalty-bearing and will comply with the terms and conditions of 35
U.S.C. 209 and 37 CFR Sec. 404.7. The prospective exclusive license may
be granted unless, within 60 days from the date of this published
notice, NIH receives written evidence and argument that establishes
that the grant of the license would not be consistent with the
requirements of 35 U.S.C. 209 and 37 CFR Sec. 404.7.
The field of use would be limited to Pseudomonas-Exotoxin-based
fusion protein cancer therapy.
The present invention relates to modifications of recombinant
Pseudomonas exotoxin with insertion of various targeting molecules
specific for a given target site. The modified exotoxin of this
invention may prove to be a valuable cancer therapeutic when fused to
various target-specific cell recognition proteins. The modifications
result in reduced non-specific cytotoxicity while increasing target
specific cytotoxicity.
ADDRESSES: Requests for a copy of the subject issued patent, inquiries,
comments and other materials relating to the contemplated license
should be directed to: Mr. Larry M. Tiffany, Office of Technology
Transfer, National Institutes of Health, 6011 Executive Boulevard,
Suite 325, Rockville, MD 20852-3804; Telephone: (301) 496-7056, ext.
206; Facsimile: (301) 402-0220.
Only written comments and/or applications for a license which are
received by the NIH Office of Technology Transfer on or before January
14, 1997 will be considered. Comments and objections will not be made
available for public inspection and, to the extent permitted by law,
will not be subject to disclosure under the Freedom of Information Act,
5 U.S.C. 552.
Dated: November 4, 1996.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 96-29255 Filed 11-14-96; 8:45 am]
BILLING CODE 4140-01-M
